Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00400816 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00400816 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 29 participants.
The verdict
NCT00400816, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with newly diagnosed anaplastic oligodendroglioma or mixed oligoastrocytoma.
Interventions
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-08 |
| Est. Completion | 2016-01-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00400816
The ClinicalTrials.gov registry entry for NCT00400816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.
NCT00400816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00400816 about?
NCT00400816 is a clinical study titled "Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with newly diagnosed anapla...
What is the current status of trial NCT00400816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-08. Estimated completion is 2016-01-06.
What interventions are being tested in trial NCT00400816?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00400816?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.